Zinc finger protein 423 (ZNF423) (ZNF423)

Zinc finger protein 423 (ZNF423) is a massive multi-zinc finger transcription factor containing 30 C2H2-type zinc fingers, which allow it to interact with a diverse array of DNA sequences and protein partners (UniProt Q2M1K9) [1]. It serves as a critical scaffold in several signaling pathways, including the Bone Morphogenetic Protein (BMP), Notch, and Retinoic Acid pathways, and is essential for normal development of the cerebellum and olfactory epithelium (NCBI Gene 23090) [2]. In clinical oncology, ZNF423 is recognized for its dual role; it acts as an oncogene in B-cell precursor acute lymphoblastic leukemia and neuroblastoma, while its dysfunction is linked to ciliopathies such as Joubert syndrome and nephronophthisis (PMID: 22842229, 24743550) [3, 4]. The ZNF423 mRNA is a potential therapeutic target for RNA-based modalities like antisense oligonucleotides (ASOs) or siRNA, particularly in cancers where its overexpression drives disease progression. Additionally, its involvement in the DNA damage response through interactions with PARP1 suggests it may influence sensitivity to DNA-damaging agents (PMID: 31434693) [5]. Understanding the regulatory network of ZNF423 is vital for developing targeted therapies that can modulate its activity without disrupting its essential developmental functions. References: [1] UniProt Q2M1K9; [2] NCBI Gene 23090; [3] PMID: 22842229; [4] PMID: 24743550; [5] PMID: 31434693.

Other names

OAZEarly B-cell factor-associated zinc finger proteinEBF-associated zinc finger proteinZFP423JBTS19NPHP14ROAZ

Antisense-mediated mRNA degradation or RNA interference to reduce protein expression levels (PMID: 24743550) [4].